To demonstrate the effectiveness of this platform we focused on four factors differentially regulated in MS lesions that influence OPC proliferation, differentiation, and myelination: platelet-derived growth factor subunit A dimer (PDGF–AA [20]), fibroblast growth factor 2 (FGF2 [15,21]), bone morphogenetic protein 2 (BMP2 [22]), and bone morphogenetic protein 4 (BMP4 [22,23]). This evidence concerns the gene BMP2 and myeloid sarcoma.